{"meshTags":["Adenocarcinoma","Antineoplastic Agents","Erlotinib Hydrochloride","Humans","Lung Neoplasms","Mutation","Neoplasm Metastasis","Proto-Oncogene Proteins","Proto-Oncogene Proteins p21(ras)","Quinazolines","Remission Induction","Time Factors","ras Proteins"],"meshMinor":["Adenocarcinoma","Antineoplastic Agents","Erlotinib Hydrochloride","Humans","Lung Neoplasms","Mutation","Neoplasm Metastasis","Proto-Oncogene Proteins","Proto-Oncogene Proteins p21(ras)","Quinazolines","Remission Induction","Time Factors","ras Proteins"],"genes":["KRAS mutations"],"publicationTypes":["Case Reports","Letter","Research Support, Non-U.S. Gov\u0027t","Review"],"title":"Durable responses to Erlotinib despite KRAS mutations in two patients with metastatic lung adenocarcinoma.","pubmedId":"20501506"}